Anti-LAG-3 Antibodies for in vivo use

ichorbio manufactures clone C9B7W, a low endotoxin anti-LAG-3 antibody for in vivo use. This antibody is available in bulk quantities with standard sizes 5mg-100mg and gram quantities readily available.

Bulk C9B7W anti-LAG-3 antibody

ichorbio manufactures a number of LAG-3 biosimilars. All of our biosimilars are provided in low endotoxin formats and so are suitable for in vivo use.

Anti-LAG-3 biosimilars

LAG-3 Background

LAG3 is also known as Lymphocyte activation gene 3 protein. LAG-3 is an inhibitory receptor on antigen activated T-cells. LAG-3 delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. LAG-3 may also inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1.

LAG-3 negatively regulates the proliferation, activation, effector function and homeostasis of both CD8⁺ and CD4⁺ T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear.